MCID: PRP021
MIFTS: 51

Peripheral Nervous System Neoplasm

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Peripheral Nervous System Neoplasm

MalaCards integrated aliases for Peripheral Nervous System Neoplasm:

Name: Peripheral Nervous System Neoplasm 12 15
Peripheral Nervous System Neoplasms 45 74
Nerve Sheath Neoplasm 12 77
Nerve Sheath Tumors 12 74
Neoplasm of Peripheral Nerve 12
Nerve Sheath Neoplasms 45
Tumor of Pns 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1192
NCIt 51 C3321 C4972

Summaries for Peripheral Nervous System Neoplasm

Disease Ontology : 12 A nervous system cancer that is located in the peripheral nervous system.

MalaCards based summary : Peripheral Nervous System Neoplasm, also known as peripheral nervous system neoplasms, is related to epithelioid malignant peripheral nerve sheath tumor and ganglioneuroma, and has symptoms including neuralgia An important gene associated with Peripheral Nervous System Neoplasm is MYCN (MYCN Proto-Oncogene, BHLH Transcription Factor), and among its related pathways/superpathways are Akt Signaling and PI3K-Akt signaling pathway. The drugs Dopamine and Methylphenidate have been mentioned in the context of this disorder. Affiliated tissues include brain, bone and skin, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 77 A nerve sheath tumor is a type of tumor of the nervous system (nervous system neoplasm) which is made up... more...

Related Diseases for Peripheral Nervous System Neoplasm

Diseases in the Peripheral Nervous System Neoplasm family:

Peripheral Nervous System Benign Neoplasm

Diseases related to Peripheral Nervous System Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 224)
# Related Disease Score Top Affiliating Genes
1 epithelioid malignant peripheral nerve sheath tumor 34.4 ENO2 NF1
2 ganglioneuroma 31.1 ENO2 MYCN NTRK1 NTRK2
3 cellular schwannoma 30.9 CD34 NF1 TP53
4 adenocarcinoma 30.7 AKT1 ALK MYC TP53
5 autonomic nervous system neoplasm 30.6 AKT1 ALK CASP3 CD177 CNTN6 ENO2
6 ewing sarcoma 30.5 AKT1 ALK CASP3 CD34 ENO2 MYC
7 meningioma, familial 30.5 AKT1 CD34 ENO2 NF1 TP53
8 pheochromocytoma 30.4 CASP3 ENO2 NF1 NGF NTRK1 TH
9 rhabdomyosarcoma 30.4 ALK ENO2 MYCN TP53
10 gastrointestinal stromal tumor 30.2 AKT1 CD34 ENO2 NF1 TP53
11 glioblastoma 30.1 AKT1 ALK MYC MYCN NF1 TP53
12 thyroid cancer 30.1 AKT1 CASP3 MYC NTRK1 TP53
13 malignant peripheral nerve sheath tumor with perineurial differentiation 12.5
14 malignant melanocytic peripheral nerve sheath tumor of mediastinum 12.4
15 malignant cardiac peripheral nerve sheath neoplasm 12.3
16 neurofibrosarcoma 12.2
17 neurofibroma 12.1
18 malignant glandular tumor of peripheral nerve sheath 11.6
19 neurilemmoma 11.6
20 malignant melanocytic neoplasm of the peripheral nerve sheath 11.5
21 malignant triton tumor 11.3
22 melanocytic psammomatous mpnst 11.3
23 chromosome 17q11.2 deletion syndrome, 1.4-mb 11.2
24 chromosome 17q11.2 deletion syndrome 11.2
25 painful orbital and systemic neurofibromas-marfanoid habitus syndrome 11.2
26 sarcoma 10.5
27 gliofibroma 10.5 NF1 TP53
28 parameningeal embryonal rhabdomyosarcoma 10.5 ALK TP53
29 central nervous system benign neoplasm 10.5 ENO2 MYCN TP53
30 prolactin producing pituitary tumor 10.5 NGF NTRK1 TP53
31 cerebral neuroblastoma 10.5 ENO2 NGF TP53
32 optic nerve neoplasm 10.5 ENO2 NF1 TP53
33 meningeal melanomatosis 10.5 ENO2 NGF TP53
34 bone ewing's sarcoma 10.5 ENO2 MYC MYCN
35 olfactory neuroblastoma 10.5 ENO2 NTRK1 NTRK2
36 juvenile pilocytic astrocytoma 10.5 ENO2 NF1 TP53
37 causalgia 10.5 ENO2 NGF NTRK1
38 intravascular fasciitis 10.5 ALK CD34
39 adult medulloblastoma 10.5 ENO2 MYCN TP53
40 plexiform schwannoma 10.5 CD34 ENO2 NF1
41 lung meningioma 10.5 CD34 ENO2
42 autonomic nervous system benign neoplasm 10.5 ENO2 MYCN NF1 NTRK1
43 ovary sarcoma 10.5 CD34 MYC
44 ovarian angiosarcoma 10.5 CD34 MYC
45 adrenal neuroblastoma 10.5 ENO2 MYCN
46 optic nerve glioma 10.5 ENO2 NF1 TP53
47 cellular neurofibroma 10.5 CD34 TP53
48 short-rib thoracic dysplasia 4 with or without polydactyly 10.5 CASP3 TP53
49 childhood medulloblastoma 10.5 MYC MYCN TP53
50 hereditary sensory neuropathy 10.4 NGF NTRK1 NTRK2

Graphical network of the top 20 diseases related to Peripheral Nervous System Neoplasm:



Diseases related to Peripheral Nervous System Neoplasm

Symptoms & Phenotypes for Peripheral Nervous System Neoplasm

UMLS symptoms related to Peripheral Nervous System Neoplasm:


neuralgia

GenomeRNAi Phenotypes related to Peripheral Nervous System Neoplasm according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 9.6 AKT1 ALK MYC NF1 NTRK2
2 Decreased viability GR00221-A-2 9.6 AKT1 NF1 NTRK2
3 Decreased viability GR00221-A-3 9.6 AKT1 MYC
4 Decreased viability GR00221-A-4 9.6 AKT1 ALK NF1 NTRK2
5 Decreased viability GR00402-S-2 9.6 AKT1 ALK MYC NF1 NTRK2

MGI Mouse Phenotypes related to Peripheral Nervous System Neoplasm:

47 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.49 AKT1 ALK CASP3 CNTN6 ENO2 MYC
2 growth/size/body region MP:0005378 10.43 AKT1 ALK CASP3 ENO2 MYC MYCN
3 cellular MP:0005384 10.35 AKT1 CASP3 CD34 ENO2 MYC MYCN
4 mortality/aging MP:0010768 10.34 AKT1 ALK CASP3 MYC MYCN NF1
5 nervous system MP:0003631 10.34 AKT1 ALK CASP3 CNTN6 ENO2 MYC
6 homeostasis/metabolism MP:0005376 10.31 AKT1 ALK CASP3 CD34 MYC MYCN
7 integument MP:0010771 10.22 AKT1 ALK CASP3 CD34 MYC NF1
8 craniofacial MP:0005382 10.11 CASP3 ENO2 MYC MYCN NF1 NFIC
9 normal MP:0002873 10.11 AKT1 MYC MYCN NF1 NGF NTRK1
10 hearing/vestibular/ear MP:0005377 10.09 CASP3 MYC NF1 NTRK1 NTRK2 NUMBL
11 muscle MP:0005369 10.08 AKT1 CASP3 MYC MYCN NF1 NGF
12 liver/biliary system MP:0005370 10.05 AKT1 MYC MYCN NF1 NTRK2 TH
13 neoplasm MP:0002006 10 AKT1 ALK CD34 MYC NF1 TH
14 no phenotypic analysis MP:0003012 9.95 CASP3 MYC MYCN NGF NTRK1 TH
15 reproductive system MP:0005389 9.91 AKT1 ALK CASP3 MYC MYCN NFIC
16 respiratory system MP:0005388 9.85 AKT1 ALK CASP3 ENO2 MYCN NF1
17 pigmentation MP:0001186 9.8 ALK CASP3 MYC NF1 NTRK1 TP53
18 skeleton MP:0005390 9.61 AKT1 ALK CASP3 MYC MYCN NF1
19 vision/eye MP:0005391 9.32 ALK CASP3 MYCN NF1 NGF NTRK1

Drugs & Therapeutics for Peripheral Nervous System Neoplasm

Drugs for Peripheral Nervous System Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 233)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Not Applicable 62-31-7, 51-61-6 681
2
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
3
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
4
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
5
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
6 Anti-Infective Agents Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
7 Gentamicins Phase 4,Not Applicable
8 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
9 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 1
10 Analgesics Phase 4,Phase 2,Phase 1
11 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 1
12 Dopamine Uptake Inhibitors Phase 4
13 Neurotransmitter Uptake Inhibitors Phase 4
14 Neurotransmitter Agents Phase 4,Phase 2,Phase 1,Not Applicable
15 Central Nervous System Stimulants Phase 4,Not Applicable
16 Dopamine Agents Phase 4,Not Applicable
17 Anesthetics Phase 4,Not Applicable
18 Central Nervous System Depressants Phase 4,Phase 2,Phase 3,Phase 1
19
Glycopyrrolate Phase 4 596-51-0 3494
20 Anesthetics, General Phase 4
21 Adrenergic alpha-Agonists Phase 4
22 Adrenergic alpha-2 Receptor Agonists Phase 4
23 Hypnotics and Sedatives Phase 4
24 Adrenergic Agents Phase 4
25 Adrenergic Agonists Phase 4
26 Anesthetics, Intravenous Phase 4
27
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
28
Temozolomide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 85622-93-1 5394
29
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1 51-75-2 4033
30
Ifosfamide Approved Phase 3,Phase 2 3778-73-2 3690
31
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
32
Carboplatin Approved Phase 3,Phase 1,Phase 2 41575-94-4 10339178 38904 498142
33
Chlorhexidine Approved, Vet_approved Phase 2, Phase 3 55-56-1 2713 9552079
34
Lamotrigine Approved, Investigational Phase 2, Phase 3 84057-84-1 3878
35
Daunorubicin Approved Phase 2, Phase 3 20830-81-3 30323
36
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
37
Calcium Approved, Nutraceutical Phase 2, Phase 3 7440-70-2 271
38
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
39 Alkylating Agents Phase 3,Phase 2,Phase 1,Early Phase 1
40 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Early Phase 1
41 Antimitotic Agents Phase 3,Phase 2,Phase 1
42 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
43 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Early Phase 1
44 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
45
Isophosphamide mustard Phase 3,Phase 2 0
46 Psychotropic Drugs Phase 2, Phase 3,Phase 1
47 Anticonvulsants Phase 2, Phase 3,Phase 1
48 Tranquilizing Agents Phase 2, Phase 3,Phase 1
49 Protein Kinase Inhibitors Phase 2, Phase 3,Phase 1,Early Phase 1
50 Imatinib Mesylate Phase 2, Phase 3,Phase 1 220127-57-1 123596

Interventional clinical trials:

(show top 50) (show all 258)
# Name Status NCT ID Phase Drugs
1 Gentamicin Treatment Prior to Schwannoma Surgery - Residual Function Unknown status NCT02379754 Phase 4 Gentamicins
2 NF1-Attention: Study of Children With Neurofibromatosis Type 1 Treated by Methylphenidate Completed NCT00169611 Phase 4 methylphenidate
3 Dexmedetomidine and Propofol for Pediatric MRI Sedation Recruiting NCT03513757 Phase 4 propofol;Dexmedetomidine
4 Gentamicin Treatment Prior to Schwannoma Surgery - No Residual Function Recruiting NCT02415257 Phase 4 Gentamicin
5 First Clinical Study of Erbium - Yttrium Aluminium Garnet (YAG) Laser Vaporization of Cutaneous Neurofibromas Unknown status NCT00921037 Phase 2, Phase 3
6 Stereotactic Radiation in Vestibular Schwannoma Unknown status NCT01449604 Phase 3
7 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
8 Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain Recruiting NCT02471339 Phase 3
9 Effect of Lamotrigine on Cognition in NF1 Recruiting NCT02256124 Phase 2, Phase 3 Lamotrigine;Placebo
10 Cyberknife Radiosurgery for Patients With Neurinomas Recruiting NCT02055859 Phase 3
11 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Active, not recruiting NCT02180867 Phase 2, Phase 3 Doxorubicin;Doxorubicin Hydrochloride;Ifosfamide;Pazopanib;Pazopanib Hydrochloride
12 Selumetinib Versus Carboplatin/Vincristine in Treating Patients With Newly Diagnosed or Previously Untreated NF1-Associated Low-Grade Glioma Not yet recruiting NCT03871257 Phase 3 Carboplatin;Selumetinib;Selumetinib Sulfate;Vincristine;Vincristine Sulfate
13 Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors Terminated NCT00427583 Phase 2, Phase 3 imatinib mesylate
14 Phase 3 Study of ANP Therapy vs. TMZ for Optic Pathway Glioma Withdrawn NCT01260103 Phase 3 Temozolomide;ANP Therapy
15 Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Unknown status NCT02934256 Phase 2 Icotinib
16 Medical Treatment of "High-Risk" Neurofibromas Unknown status NCT00846430 Phase 2 Peg-Interferon alpha-2b;Celecoxib (Celebrex);Temozolomide (temodar);Vincristine Sulfate (Oncovin)
17 Use of Topical Liquid Diclofenac Following Laser Microporation of Cutaneous Neurofibromas in Patients With NF1 Completed NCT03090971 Phase 2 Diclofenac Sodium;Saline Solution
18 SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors) Completed NCT02008877 Phase 1, Phase 2 ganetespib;Sirolimus
19 SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors Completed NCT01661283 Phase 2 everolimus;bevacizumab
20 Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T Completed NCT02332902 Phase 2 Everolimus
21 Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Completed NCT02104323 Phase 2 Endostatin
22 MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1 Completed NCT02096471 Phase 2 PD-0325901
23 Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas Completed NCT01673009 Phase 2 Gleevec
24 Alisertib in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01653028 Phase 2 Alisertib
25 Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma Completed NCT01614795 Phase 2 Temsirolimus
26 Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients Completed NCT01490476 Phase 2 RAD001
27 Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2 Completed NCT01419639 Phase 2 Everolimus (RAD001) , Afinitor®
28 Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas Completed NCT01412892 Phase 2 RAD001: Everolimus
29 Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2) Completed NCT01207687 Phase 2
30 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
31 Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas Completed NCT01140360 Phase 1, Phase 2 Gleevec
32 Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Completed NCT00973739 Phase 2 Lapatinib
33 Study of PEG-Intron for Plexiform Neurofibromas Completed NCT00396019 Phase 2 PEG-Intron
34 A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1 Completed NCT00853580 Phase 2 Lovastatin ™
35 Sorafenib and Dacarbazine in Soft Tissue Sarcoma Completed NCT00837148 Phase 2 Sorafenib and Dacarbazine
36 Clinical Trial of Pirfenidone in Adult Patients With Neurofibromatosis 1 Completed NCT00754780 Phase 2 Pirfenidone
37 Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy Completed NCT00679354 Phase 2 cilengitide
38 A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas Completed NCT00634270 Phase 2 Sirolimus
39 Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma Completed NCT00589784 Phase 2 Sunitinib
40 Trial of Dasatinib in Advanced Sarcomas Completed NCT00464620 Phase 2 Dasatinib
41 S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor Completed NCT00068367 Phase 2 erlotinib hydrochloride
42 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors Completed NCT00304083 Phase 2 doxorubicin hydrochloride;etoposide;ifosfamide
43 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2 sorafenib tosylate
44 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Completed NCT00112463 Phase 2 romidepsin
45 Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Completed NCT00091182 Phase 2 oxaliplatin
46 Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas Completed NCT00076102 Phase 2 Pirfenidone
47 Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma Completed NCT00070525 Phase 2 tipifarnib
48 Irinotecan in Treating Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
49 Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas Completed NCT00030264 Phase 2 Methotrexate;Vinblastine
50 Antineoplaston Therapy in Treating Children With Visual Pathway Glioma Completed NCT00003477 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)

Search NIH Clinical Center for Peripheral Nervous System Neoplasm

Cochrane evidence based reviews: peripheral nervous system neoplasms

Genetic Tests for Peripheral Nervous System Neoplasm

Anatomical Context for Peripheral Nervous System Neoplasm

MalaCards organs/tissues related to Peripheral Nervous System Neoplasm:

42
Brain, Bone, Skin, Pituitary, Thyroid, T Cells, Spinal Cord

Publications for Peripheral Nervous System Neoplasm

Articles related to Peripheral Nervous System Neoplasm:

# Title Authors Year
1
Recent Advances in the Diagnosis and Pathogenesis of Neurofibromatosis Type 1 (NF1)-associated Peripheral Nervous System Neoplasms. ( 29762158 )
2018

Variations for Peripheral Nervous System Neoplasm

Expression for Peripheral Nervous System Neoplasm

Search GEO for disease gene expression data for Peripheral Nervous System Neoplasm.

Pathways for Peripheral Nervous System Neoplasm

Pathways related to Peripheral Nervous System Neoplasm according to GeneCards Suite gene sharing:

(show all 36)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.36 AKT1 ALK CASP3 NGF NTRK1 NTRK2
2
Show member pathways
12.94 AKT1 CASP3 MYC NGF NTRK1 NTRK2
3 12.81 AKT1 ALK CASP3 MYC NTRK1 TP53
4
Show member pathways
12.8 AKT1 CASP3 MYC NTRK1 TP53
5
Show member pathways
12.78 AKT1 CASP3 MYC NGF NTRK1 TP53
6
Show member pathways
12.69 AKT1 NF1 NGF NTRK1 NTRK2
7
Show member pathways
12.67 AKT1 CASP3 NGF NTRK1 NTRK2 TP53
8
Show member pathways
12.42 AKT1 CASP3 MYC TH
9
Show member pathways
12.4 AKT1 CASP3 NTRK1 NTRK2 TP53
10 12.4 ENO2 MYCN NF1 NGF NTRK1 NTRK2
11 12.25 AKT1 CASP3 MYC TP53
12 12.21 MYC MYCN NTRK1 TP53
13
Show member pathways
12.21 AKT1 MYC NGF NTRK1 NTRK2 TP53
14 12.15 AKT1 CASP3 MYC TP53
15 12.12 CASP3 NGF NTRK2 PHOX2B TH
16 12.08 AKT1 CASP3 MYC NF1 TP53
17
Show member pathways
12.03 AKT1 CASP3 MYC NTRK1 NTRK2 TP53
18 12.01 AKT1 CASP3 NGF NTRK1 NTRK2
19 11.94 AKT1 MYC NF1 TP53
20 11.89 AKT1 CASP3 MYC NTRK1 NTRK2 TP53
21 11.89 AKT1 CASP3 MYC NF1 NGF NTRK1
22 11.85 AKT1 CASP3 MYC TP53
23 11.69 AKT1 CASP3 TP53
24
Show member pathways
11.67 AKT1 CASP3 NGF TP53
25 11.65 AKT1 MYC NTRK1 TP53
26
Show member pathways
11.61 AKT1 CASP3 MYC NGF NTRK1 TP53
27
Show member pathways
11.6 NGF NTRK1 NTRK2
28 11.54 AKT1 CASP3 TP53
29 11.45 NGF NTRK1 NTRK2
30 11.44 AKT1 CASP3 MYC TP53
31 11.37 AKT1 CASP3 MYC TP53
32 11.37 AKT1 CNTN6 MYC MYCN TP53
33 11.29 AKT1 CASP3 NGF
34 10.81 CASP3 NTRK2
35
Show member pathways
10.69 NGF NTRK1 NTRK2
36 10.32 MYC MYCN

GO Terms for Peripheral Nervous System Neoplasm

Cellular components related to Peripheral Nervous System Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.97 AKT1 CASP3 CD34 ENO2 MYC NF1
2 dendrite GO:0030425 9.35 NF1 NGF NTRK1 NTRK2 TH
3 axon GO:0030424 9.1 CNTN6 NF1 NGF NTRK1 NTRK2 TH

Biological processes related to Peripheral Nervous System Neoplasm according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 cell proliferation GO:0008283 9.97 AKT1 ALK CD34 MYC TP53
2 negative regulation of gene expression GO:0010629 9.94 AKT1 CD34 MYC MYCN
3 positive regulation of apoptotic process GO:0043065 9.93 AKT1 CASP3 NF1 NGF TP53
4 nervous system development GO:0007399 9.88 AKT1 ALK CNTN6 NTRK1 NTRK2 NUMBL
5 protein autophosphorylation GO:0046777 9.86 AKT1 ALK NTRK1 NTRK2
6 cytokine-mediated signaling pathway GO:0019221 9.85 AKT1 CASP3 MYC NUMBL TP53
7 neuron differentiation GO:0030182 9.81 CASP3 CNTN6 NTRK2 PHOX2B
8 cerebral cortex development GO:0021987 9.8 NF1 NTRK2 TH
9 cellular response to organic cyclic compound GO:0071407 9.79 AKT1 CASP3 MYC
10 cellular response to drug GO:0035690 9.79 MYC TH TP53
11 cellular response to growth factor stimulus GO:0071363 9.77 AKT1 NTRK1 TH
12 negative regulation of neuron death GO:1901215 9.76 AKT1 CD34 NTRK1
13 positive regulation of protein phosphorylation GO:0001934 9.75 AKT1 NTRK1 NTRK2
14 response to nicotine GO:0035094 9.7 CASP3 NTRK1 TH
15 positive regulation of gene expression GO:0010628 9.7 AKT1 CD34 MYC MYCN NGF NTRK2
16 cellular response to nerve growth factor stimulus GO:1990090 9.67 AKT1 NTRK1 NTRK2
17 striated muscle cell differentiation GO:0051146 9.65 AKT1 CASP3
18 nerve growth factor signaling pathway GO:0038180 9.64 NGF NTRK1
19 positive regulation of mitochondrial membrane potential GO:0010918 9.63 AKT1 MYC
20 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.62 MYCN TP53
21 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.62 ALK NGF NTRK1 NTRK2
22 negative regulation of fibroblast proliferation GO:0048147 9.61 MYC NF1 TP53
23 cellular response to nicotine GO:0071316 9.6 NTRK1 TH
24 mechanoreceptor differentiation GO:0042490 9.55 NTRK1 NTRK2
25 response to gamma radiation GO:0010332 9.54 MYC TP53 TRIM13
26 neurotrophin signaling pathway GO:0038179 9.48 NTRK1 NTRK2
27 sympathetic nervous system development GO:0048485 9.43 NF1 NTRK1 PHOX2B
28 negative regulation of apoptotic process GO:0043066 9.43 AKT1 CASP3 MYC NGF NTRK1 TP53
29 neurotrophin TRK receptor signaling pathway GO:0048011 8.92 CASP3 NGF NTRK1 NTRK2
30 negative regulation of cell proliferation GO:0008285 10 NF1 NGF NTRK1 PHOX2B TP53

Molecular functions related to Peripheral Nervous System Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.65 MYC MYCN NFIC PHOX2B TP53
2 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.33 ALK NTRK1 NTRK2
3 neurotrophin binding GO:0043121 8.96 NTRK1 NTRK2
4 neurotrophin receptor activity GO:0005030 8.62 NTRK1 NTRK2

Sources for Peripheral Nervous System Neoplasm

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....